Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP142) admin

详细信息    查看全文

• 作者：Nekoye Otsyula (1)
  Evelina Angov (2)
  Elke Bergmann-Leitner (2)
  Margaret Koech (1)
  Farhat Khan (2)
  Jason Bennett (2)
  Lucas Otieno (1)
  James Cummings (2)
  Ben Andagalu (1)
  Donna Tosh (2)
  John Waitumbi (1)
  Nancy Richie (2)
  Meng Shi (2)
  Lori Miller (2)
  Walter Otieno (1)
  Godfrey Allan Otieno (1)
  Lisa Ware (2)
  Brent House (2)
  Olivier Godeaux (3)
  Marie-Claude Dubois (3)
  Bernhards Ogutu (1)
  W Ripley Ballou (3)
  Lorraine Soisson (4)
  Carter Diggs (4)
  Joe Cohen (3)
  Mark Polhemus (2)
  D Gray Heppner Jr (2)
  Christian F Ockenhouse (2)
  Michele D Spring (2)
  
• 关键词：Malaria ; Vaccine ; Merozoite surface protein ; 1 ; Plasmodium
• 刊名：Malaria Journal
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：12
• 期：1
• 全文大小：328KB
• 参考文献：1. RTS,S Clinical Trial Partnership: First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children. / N Engl J Med 2011, 365:1863-875. CrossRef
  2. Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L: Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. / Vaccine 2005, 18:2243-250. et al CrossRef
  3. Hui GS, Gosnell WL, Case SE, Hashiro D, Nikaido C, Hashimoto A, Kaslow DC: Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP119 expressed in S. cerevisiae. / J Immunol 1994, 153:2544-553.
  4. Udhayakumar V, Anyona D, Kariuki S, Shi YP, Bloland PB, Branch OH, Weiss W, Nahlen BL, Kaslow DC, Lal AA: Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP1). / J Immunol 1995, 154:6022-030.
  5. Renia L, Ling IT, Marussig M, Miltgen F, Holder AA, Mazier D: Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. / Infect Immun 1997, 65:4419-423.
  6. Lyon JA, Angov E, Kay MP, Sullivan JS, Giroud AS, Robinson SJ, Bergmann-Leitner ES, Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW: Protection induced by Plasmodium falciparum MSP142 is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. / PLoS One 2008, 3:e2830. CrossRef
  7. Angov E, Aufiero BA, Van Handenhove M, Ockenhouse CF, Kester K, Walsh D, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DH, Ballou WR, Diggs CL, Lyon JA: Development and preclinical analysis of a recombinant P. falciparum Merozoite Surface Protein-142 malaria vaccine. / Mol Biochem Parasitol 2003, 128:195-04. CrossRef
  8. Ockenhouse CF, Angov EA, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart VA, Palmer DP, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG: Phase 1 safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. / Vaccine 2006, 24:3009-017. CrossRef
  9. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov EA, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs CL, Wittes J, Heppner DG: Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. / Vaccine 2006, 25:176-84. CrossRef
  10. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Stewart VA, Angov EA, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV, Mali FMP1 Working Group: Safety and allele specific immunogenicity of a malaria vaccine in adults: Results of a Phase 1 randomized trial. / PLoS Clin Trials 2006, 1:e34. CrossRef
  11. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, Apollo OJ, Allen OG, Tucker K, Soisson LA, Diggs C, Leach A, Wittes J, Dubovsky F, Stewart VA, Remich SA, Cohen J, Ballou WR, Holland CA, Lyon JA, Angov EA, Stoute JA, Martin SK, Heppner DG, MSP-1 Malaria Vaccine Working Group: Safety and Reactogenicity of an MSP-1 malaria vaccine candidate: A randomized Phase 1b dose escalation trial in Kenyan children. / PLoS Clin Trials 2006, 1:e32. CrossRef
  12. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov EA, Stewart VA, Lyon JA, Heppner DG, MR for the MSP-1 Malaria Vaccine Working Group: Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. / PLoS One 2009, 4:e4708. CrossRef
  13. Genton B, Betuela I, Felger I, Al-Yaman A, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP: A recombinant blood stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase 1-b trial in Papua New Guinea. / J Infect Dis 2002, 185:820-27. CrossRef
  14. Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW: Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. / Infect Immun 2003, 71:6766-774. CrossRef
  15. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA: Clinical grade Plasmodium falciparum FVO MSP142 Expressed in Escherichia coli protects Aotus nancymai against homologous erythrocytic-stage challenge. / Infect Immun 2005, 73:287-97. CrossRef
  16. Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT, Hui GS: A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. / Infect Immun 1996, 64:253-61.
  17. Stowers AW, Chen LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH: A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. / Proc Natl Acad Sci USA 2002, 99:339-44. CrossRef
  18. Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH: Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. / Infect Immun 2001, 69:1536-546. CrossRef
  19. Persson KE, Lee CT, Marsh K, Beeson JG: Development and optimization of high throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. / J Clin Microbiol 2006, 44:1665-673. CrossRef
  20. Bergmann-Leitner ES, Duncan EH, Burge JR, Spring M, Angov E: Miniaturization of a high-throughput pLDH-based Plasmodium falciparum growth inhibition assay for small volume samples from preclinical and clinical vaccine trials. / Am J Trop Med Hyg 2008, 78:468-71.
  21. Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, Cummings JF, Kester KE, Ockenhouse CF, Stewart A, Ofori-Anyinam O, Ramboer I, Cahill CP, Lievens M, Dubois MC, Demoitie MA, Leach A, Cohen J, Ballou WR, Heppner DG Jr: Evaluation of RTS, S/AS02A and RTS, S/AS01B in adults in a high malaria transmission area. / PLoS One 2009, 4:e6465. CrossRef
  22. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reideler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MK, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, De Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC: Phase 1/2a study comparing the safety, immunogenicity and efficacy of the malaria vaccine candidate Apical Membrane Antigen-1 (AMA-1) in adjuvant AS01B or AS02A in malaria-na?ve adults. / PLoS One 2009, 4:e5254. et al CrossRef
  23. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG: Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. / Vaccine 2009, 28:5135-144. CrossRef
  24. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG Jr, RTS, S Vaccine Evaluation Group: Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. / J Infect Dis 2009, 200:337-46. CrossRef
  25. Dluzewski AR, Ling IT, Hopkins JM, Grainger M, Margos G, Mitchell GH, Holder AA, Bannister LH: Formation of the food vacuole in Plasmodium falciparum: a potential role for the 19 kDa fragment of merozoite surface protein 1 (MSP1(19)). / PLoS One 2008, 3:e3085. CrossRef
  26. Bergmann-Leitner ES, Duncan EH, Angov E: MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum. / Malar J 2009, 8:183. CrossRef
  27. Malkin E, Long CA, Stowers AW, Zou L, Singh S, MacDonald NJ, Narum DL, Miles AP, Orcutt AC, Muratova O, MOretz SE, Zhou H, Diouf A, Fay M, Tierney E, Leese P, Mahanty S, Miller LH, Saul A, Marton LB: Phase 1 study of two merozoite surface protein 1 (MSP142) vaccines for Plasmodium falciparum malaria. / PLoS Clin Trials 2007, 2:e12. CrossRef
  28. Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, Narum DL, Zhu D, Mullen GED, Mahanty S, Miller LH, Durbin AP: Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria na?ve adults. / PLoS One 2010, 5:e8787. CrossRef
  29. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, Sumba PO, Beeson JG, Angov EA, Moormann AM, Kazura JW: Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. / PLoS One 2008, 3:e3557. CrossRef
  30. Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, Trape JF, Longacre S, Mercereau-Puijalon O: Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. / J Infect Dis 2005, 191:264-71. CrossRef
  31. Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, Gaye O, Roeffen W, Remarque EJ, Sauerwein R, Garcia A, Luty AJF: The quantity and quality of African children’s IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. / PLoS One 2009, 4:e7590. CrossRef
  32. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, Williams TN, Marsh K, Beeson JG: Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. / PLoS One 2008, 3:e3571. CrossRef
  33. Crompton PD, Miura K, Traore B, Kayentao K, Ongoiba A, Weiss G, Doumbo S, Doumtabe D, Kone Y, Huang CY, Doumbo OK, Miller LH, Long CA, Pierce SK: In vitro growth inhibitory activity and malaria risk in a cohort study in Mali. / Infect Immun 2010, 78:737-45. CrossRef
  34. Holder AA, Guevara Pati?o JA, Uthaipibull C, Syed SE, Ling IT, Scott-Finnigan T, Blackman MJ: Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. / Parassitologia 1999, 41:409-14.
  35. Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Odaibo AB, Holder AA, Nwagwu M: The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. / Infect Immun 2002, 70:5328-331. CrossRef
  36. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, Egwang TG, Holder AA, Riley EM: Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP1(19), predicts protection from malaria infection and high-density parasitemia. / Infect Immun 2004, 72:1557-567. CrossRef
  37. De Koning-Ward TF, O’Donnell RA, Drew DR, Thomson R, Speed TP, Crabb BS: A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. / J Exp Med 2003, 198:869-75. m.20030085">CrossRef
  38. Galamo CD, Jafarshad A, Blanc C, Druilhe P: Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition. / J Infect Dis 2009, 199:1151-154. CrossRef
  39. McIntosh RS, Shi J, Jennings RM, Chappel JC, De Koning-Ward TF, Smith T, Green J, Van Egmond M, Leusen JHW, Lazarou M, Van de Winkel J, Jones TS, Crabb BS, Holder AA, Pleass RJ: The importance of human FcgammaRI in mediating protection to malaria. / PLoS Pathog 2007, 3:e72. CrossRef
  
• 作者单位：Nekoye Otsyula (1)
  Evelina Angov (2)
  Elke Bergmann-Leitner (2)
  Margaret Koech (1)
  Farhat Khan (2)
  Jason Bennett (2)
  Lucas Otieno (1)
  James Cummings (2)
  Ben Andagalu (1)
  Donna Tosh (2)
  John Waitumbi (1)
  Nancy Richie (2)
  Meng Shi (2)
  Lori Miller (2)
  Walter Otieno (1)
  Godfrey Allan Otieno (1)
  Lisa Ware (2)
  Brent House (2)
  Olivier Godeaux (3)
  Marie-Claude Dubois (3)
  Bernhards Ogutu (1)
  W Ripley Ballou (3)
  Lorraine Soisson (4)
  Carter Diggs (4)
  Joe Cohen (3)
  Mark Polhemus (2)
  D Gray Heppner Jr (2)
  Christian F Ockenhouse (2)
  Michele D Spring (2)
  
  1. Walter Reed Project, Kenya Medical Research Institute, Kisumu, Kenya
  2. Malaria Vaccine Branch, Walter Reed Army Institute of Research, 2460 Linden Lane, Bldg #503, Silver Spring, USA
  3. GlaxoSmithKline Biologicals, Rue de l’Institut 89, Rixensart, Belgium
  4. US Agency for International Development, 1300 Pennsylvania Avenue, Washington DC, 20523, USA
  

文摘

Background The development of an asexual blood stage vaccine against Plasmodium falciparum malaria based on the major merozoite surface protein-1 (MSP1) antigen is founded on the protective efficacy observed in preclinical studies and induction of invasion and growth inhibitory antibody responses. The 42 kDa C-terminus of MSP1 has been developed as the recombinant protein vaccine antigen, and the 3D7 allotype, formulated with the Adjuvant System AS02A, has been evaluated extensively in human clinical trials. In preclinical rabbit studies, the FVO allele of MSP142 has been shown to have improved immunogenicity over the 3D7 allele, in terms of antibody titres as well as growth inhibitory activity of antibodies against both the heterologous 3D7 and homologous FVO parasites. Methods Two Phase 1 clinical studies were conducted to examine the safety, reactogenicity and immunogenicity of the FVO allele of MSP142 in the adjuvant system AS01 administered intramuscularly at 0-, 1-, and 2-months: one in the USA and, after evaluation of safety data results, one in Western Kenya. The US study was an open-label, dose escalation study of 10 and 50 μg doses of MSP142 in 26 adults, while the Kenya study, evaluating 30 volunteers, was a double-blind, randomized study of only the 50 μg dose with a rabies vaccine comparator. Results In these studies it was demonstrated that this vaccine formulation has an acceptable safety profile and is immunogenic in malaria-na?ve and malaria-experienced populations. High titres of anti-MSP1 antibodies were induced in both study populations, although there was a limited number of volunteers whose serum demonstrated significant inhibition of blood-stage parasites as measured by growth inhibition assay. In the US volunteers, the antibodies generated exhibited better cross-reactivity to heterologous MSP1 alleles than a MSP1-based vaccine (3D7 allele) previously tested at both study sites. Conclusions Given that the primary effector mechanism for blood stage vaccine targets is humoral, the antibody responses demonstrated to this vaccine candidate, both quantitative (total antibody titres) and qualitative (functional antibodies inhibiting parasite growth) warrant further consideration of its application in endemic settings. Trial registrations Clinical Trials NCT00666380